Last reviewed · How we verify
Gadopentetate-Dimeglumine 0.0125 mmol
Gadopentetate-Dimeglumine 0.0125 mmol is a Gadolinium-based contrast agent Small molecule drug developed by Paracelsus Medical University. It is currently FDA-approved for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs. Also known as: Magnevist.
Gadopentetate dimeglumine is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by altering the relaxation properties of water protons.
Gadopentetate dimeglumine is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by altering the relaxation properties of water protons. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs.
At a glance
| Generic name | Gadopentetate-Dimeglumine 0.0125 mmol |
|---|---|
| Also known as | Magnevist |
| Sponsor | Paracelsus Medical University |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation time) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Gadopentetate dimeglumine is a paramagnetic gadolinium chelate complex that distributes into the extracellular space following intravenous administration. The gadolinium ion shortens the T1 relaxation time of nearby water molecules, resulting in increased signal intensity on T1-weighted MRI images. This enhancement allows improved visualization and characterization of tissues and lesions during diagnostic MRI procedures.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including liver, kidney, and other organs
Common side effects
- Gadolinium retention in tissues
- Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment
- Injection site reactions
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadopentetate-Dimeglumine 0.0125 mmol CI brief — competitive landscape report
- Gadopentetate-Dimeglumine 0.0125 mmol updates RSS · CI watch RSS
- Paracelsus Medical University portfolio CI
Frequently asked questions about Gadopentetate-Dimeglumine 0.0125 mmol
What is Gadopentetate-Dimeglumine 0.0125 mmol?
How does Gadopentetate-Dimeglumine 0.0125 mmol work?
What is Gadopentetate-Dimeglumine 0.0125 mmol used for?
Who makes Gadopentetate-Dimeglumine 0.0125 mmol?
Is Gadopentetate-Dimeglumine 0.0125 mmol also known as anything else?
What drug class is Gadopentetate-Dimeglumine 0.0125 mmol in?
What development phase is Gadopentetate-Dimeglumine 0.0125 mmol in?
What are the side effects of Gadopentetate-Dimeglumine 0.0125 mmol?
What does Gadopentetate-Dimeglumine 0.0125 mmol target?
Related
- Drug class: All Gadolinium-based contrast agent drugs
- Target: All drugs targeting Water proton relaxation (T1 relaxation time)
- Manufacturer: Paracelsus Medical University — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for MRI contrast enhancement for central nervous system imaging
- Indication: Drugs for MRI contrast enhancement for body imaging including liver, kidney, and other organs
- Also known as: Magnevist
- Compare: Gadopentetate-Dimeglumine 0.0125 mmol vs similar drugs
- Pricing: Gadopentetate-Dimeglumine 0.0125 mmol cost, discount & access